Whitney Ijem

Stock Analyst at Canaccord Genuity

(0)
# 4379
Out of 5,285 analysts
103
Total ratings
35.94%
Success rate
-15.17%
Average return
21 Stocks
Name Action Price Target Current % Upside Ratings Updated
VERV Verve Therapeutics
Maintains: Strong Buy
32 39
5.46 614.29% 5 Apr 15, 2025
RYTM Rhythm Pharmaceutica...
Maintains: Strong Buy
81 92
59.95 53.46% 7 Apr 8, 2025
ALNY Alnylam Pharmaceutic...
Maintains: Strong Buy
385 390
241.97 61.18% 8 Mar 21, 2025
RGLS Regulus Therapeutics
Maintains: Buy
28 28
2.55 998.04% 5 Mar 17, 2025
GBIO Generation Bio
Maintains: Buy
9 9
0.45 1900% 2 Mar 17, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
18 6
0.45 1233.33% 6 Mar 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
74 68
12.68 436.28% 5 Mar 10, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
39 36
7.16 402.79% 6 Mar 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
39 39
26.75 45.79% 2 Feb 26, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
121 136
37.31 264.51% 8 Feb 18, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Hold
408 424
492.8 -13.96% 8 Feb 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
90 90
8.1 1011.11% 5 Nov 19, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
6 8
1.81 341.99% 8 Nov 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
13 13
0.34 3723.53% 6 Nov 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
148 150
59.63 151.55% 3 Nov 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Hold
93 84
61.97 35.55% 8 Oct 30, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
6 30
n/a n/a 2 Jul 5, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
260
n/a n/a 1 Feb 7, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Jan 21, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
120 240
6.2 3770.97% 4 Jul 23, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
33 0
n/a n/a 2 Feb 26, 2018